Skip to content
Drybench

Drybench Patent.

DABIGATRAN ETEXILATE MESYLATE, NDA 022512

The patents and exclusivities FDA's Orange Book lists for NDA 022512 as captured on 14 October 2026, each date named by its rule and its rows, and the rows of FDA's Paragraph IV list that give this NDA's number, as captured on 17 October 2026. Listed protection is a range of dates, never one date.

FDA capture · review pending. Each row is shown as captured from FDA's Orange Book files and Paragraph IV list. Dates are FDA's own; spreadsheet day numbers are shown as dates, and a cell that cannot be read as one date is shown as written and left out of the range. Where FDA lists a *PED row without flags, its flags are read from the base row and marked so. A Paragraph IV row is placed here only by the number in its RLD/NDA cell; nothing is joined by name. How this page reads FDA's files has not been independently reviewed by a regulatory-affairs reviewer.

Orange Book captured
14 October 2026
Paragraph IV list captured
17 October 2026
Last checked
30 October 2026
Data-branch commit
dadcab56563716abea6c5e31a5e1970080c778ef

Listed protection is a range of the dates FDA lists, not a forecast of market entry, and not legal, regulatory or investment advice.

Dates as listed in FDA's Orange Book capture of 14 October 2026. This page does not say whether a date has passed; compare it with today's date and FDA's current Orange Book. This page shows only what the capture of 14 October 2026 lists. It does not show patents or exclusivities listed before and since removed.

Open in the appDABIGATRAN ETEXILATE MESYLATE in the molecule app

Listed protection

Listed dates run from 7 Sep 2025 to 20 Jul 2031, each by its own rule; no one date stands for this product.

Earliest listed date
7 Sep 2025US 7,932,273, substance and product patentRule R1 · Products 001, 002, 003 · patent.txt lines 2,014, 2,018, 2,022
Latest listed date
20 Jul 2031US 9,034,822 with pediatric exclusivity, as listedRule R2 · Products 001, 002, 003 · patent.txt lines 2,015, 2,019, 2,023
Latest substance patent
7 Mar 2026US 7,932,273 with pediatric exclusivity, as listedRule R2 · Products 001, 002, 003 · patent.txt lines 2,013, 2,017, 2,021
Latest listed patent
20 Jul 2031US 9,034,822 with pediatric exclusivity, as listedRule R2 · Products 001, 002, 003 · patent.txt lines 2,015, 2,019, 2,023
Latest exclusivity
None listed

3 use-code patents, blocking the coded use only

Products

Each product number FDA lists under NDA 022512, as listed. The sections below name products by these numbers.

  • Product 001 · PRADAXA

    Dosage form; route
    CAPSULE;ORAL
    Strength
    EQ 75MG BASE
    Approval date as listed
    19 Oct 2010
    Type as listed
    RX
    Applicant as listed
    BOEHRINGER INGELHEIM PHARMACEUTICALS INC

  • Product 002 · PRADAXA

    Dosage form; route
    CAPSULE;ORAL
    Strength
    EQ 150MG BASE
    Approval date as listed
    19 Oct 2010
    Type as listed
    RX
    Applicant as listed
    BOEHRINGER INGELHEIM PHARMACEUTICALS INC

  • Product 003 · PRADAXA

    Dosage form; route
    CAPSULE;ORAL
    Strength
    EQ 110MG BASE
    Approval date as listed
    20 Nov 2015
    Type as listed
    RX
    Applicant as listed
    BOEHRINGER INGELHEIM PHARMACEUTICALS INC

Listed patents

Every patent the FDA lists for this product, as the application holder submitted it, with its flags. The FDA does not verify listings.

4 entries from 12 rows as listed; rows merge only where every cell shown is the same, each with its product numbers.

  • US 7,932,273, substance and product patent

    patent.txt lines 2,014, 2,018, 2,022
    Expiry as listed
    7 Sep 2025
    Rule
    R1
    Flags
    substance · product
    Product numbers
    001, 002, 003

  • US 7,932,273 with pediatric exclusivity, as listed

    patent.txt lines 2,013, 2,017, 2,021
    Expiry as listed
    7 Mar 2026
    Rule
    R2
    Flags
    substance · product · pediatric, as listed by FDA (from the base row)
    Product numbers
    001, 002, 003

  • US 9,034,822, use patent

    patent.txt lines 2,016, 2,020, 2,024
    Expiry as listed
    20 Jan 2031
    Rule
    R1
    Flags
    use code U-1759
    Product numbers
    001, 002, 003

  • US 9,034,822 with pediatric exclusivity, as listed

    patent.txt lines 2,015, 2,019, 2,023
    Expiry as listed
    20 Jul 2031
    Rule
    R2
    Flags
    pediatric, as listed by FDA (from the base row)
    Product numbers
    001, 002, 003

Listed exclusivities

Each exclusivity FDA lists for NDA 022512, with its code, FDA's definition of the code where the store's code list gives one, and its date as listed.

The Orange Book capture of 14 October 2026 lists no exclusivity for NDA 022512.

Paragraph IV list rows giving NDA 022512

The rows of FDA's Paragraph IV certifications list as captured on 17 October 2026 whose RLD/NDA cell gives NDA 022512, each cell as listed.

FDA's Paragraph IV list names no patent number, so it does not say which of the patents on this page an applicant certified against.

The list gives the last qualifying patent's expiry without pediatric exclusivity; in the app's Patents view, the Orange Book lists any *PED period as a separate row with its own date. The two dates describe different things. A blank cell is one FDA left blank in its list. Dates are FDA's own; the last qualifying patent expiry is not recomputed from the Orange Book.

Rows whose RLD/NDA cell we could not read as exactly one NDA number are kept apart on the list page; some may concern this product.

Rows on FDA's Paragraph IV list whose RLD/NDA cell gives NDA 022512

  • Dabigatran Etexilate Mesylate · Capsules · eq. to 75 mg base and 150 mg base

    RLD/NDA as listed: Pradaxa 22512
    First PIV submission
    20 Oct 2014
    ANDAs
    17
    180-day status
    Eligible
    Decision posted
    15 Jun 2020
    First applicant approval
    11 Mar 2020
    First marketing
    75 mg - 7/1/2022 150 mg-3/11/2020
    Last qualifying patent expiry (as listed by FDA)
    31 Aug 2027

  • Dabigatran Etexilate Mesylate · Capsules · eq. to 110 mg base

    RLD/NDA as listed: Pradaxa 22512
    First PIV submission
    15 Dec 2015
    ANDAs
    2
    180-day status
    Eligible
    Decision posted
    8 Jan 2024
    First applicant approval
    15 Dec 2023
    First marketing
    13 Feb 2024
    Last qualifying patent expiry (as listed by FDA)
    20 Jan 2031

Notes from the trace

  • R6 tentative approvals: not in the Orange Book data files as captured; the Drugs@FDA join is a later ruling.

Patents vs FDA exclusivityHow to read the Orange Book data filesParagraph IV certificationWhat changed, by week